Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1260

—

3a412030-357b-5555-8a58-45b740dee1a9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.240
  • DNA_REPAIR+0.229
  • PI3K_AKT_MTOR_SIGNALING+0.168
  • UNFOLDED_PROTEIN_RESPONSE+0.125
  • GLYCOLYSIS+0.116
  • HYPOXIA+0.107
  • WNT_BETA_CATENIN_SIGNALING+0.080
  • XENOBIOTIC_METABOLISM+0.064
  • APICAL_SURFACE+0.062
  • BILE_ACID_METABOLISM+0.054

Top 10 suppressed

  • INFLAMMATORY_RESPONSE-0.481
  • ALLOGRAFT_REJECTION-0.480
  • INTERFERON_GAMMA_RESPONSE-0.398
  • IL6_JAK_STAT3_SIGNALING-0.374
  • E2F_TARGETS-0.354
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.314
  • TNFA_SIGNALING_VIA_NFKB-0.296
  • KRAS_SIGNALING_UP-0.295
  • PANCREAS_BETA_CELLS-0.289
  • INTERFERON_ALPHA_RESPONSE-0.284

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG219
mng-umap@100
——0.915
29f9dec84-0c2c-4f85-8024-b8fb1de1eb81
colon-landscapes@1
——0.880
3SRR8613720
breast-umap@18
—C0.827
4SRR815232
brain-umap@2
GTEX—0.813
5MDT-AP-0602
medullo-epn-umap@date-based
MedMedulloblastoma0.809
6MDT-AP-2588
medullo-epn-umap@date-based
MedMedulloblastoma0.806
7MDT-AP-1362
medullo-epn-umap@date-based
MedMedulloblastoma0.798
8MDT-AP-1357
medullo-epn-umap@date-based
MedMedulloblastoma0.797
9MNG848
mng-umap@100
——0.795
10TCGA-B6-A0I8-01A-11R-A034-07
breast-umap@18
—B0.785

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.240Remibrutinib— uncovered
DNA_REPAIR0.229Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.168Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.125Idelalisib— uncovered
GLYCOLYSIS0.116Inavolisib— uncovered
HYPOXIA0.107Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.080Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.064Inavolisib— uncovered
APICAL_SURFACE0.062Temsirolimus— uncovered
BILE_ACID_METABOLISM0.054Inavolisib— uncovered
APICAL_JUNCTION0.045Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.040Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.040Inavolisib— uncovered
UV_RESPONSE_UP0.038Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.037Remibrutinib— uncovered
ADIPOGENESIS0.033Inavolisib— uncovered
HEME_METABOLISM0.033Temsirolimus— uncovered
MYOGENESIS0.032Inavolisib— uncovered
NOTCH_SIGNALING0.028Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.005Idelalisib— uncovered